[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340038-105":59,"doc-detail-340038-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","value-of-cdr1-as-as-a-predictive-and-prognostic-biomarker-for-patients-with-breast-cancer-receiving-neoadjuvant-chemotherapy-research-findings","Value of CDR1-AS as a predictive and prognostic biomarker for patients with breast cancer receiving neoadjuvant chemotherapy - Research findings","","Neoadjuvant chemotherapy (NAC) improves outcomes for locally advanced breast cancer, yet there is no robust biomarker to evaluate treatment efficacy. This study investigates CDR1-AS, a circular RNA previously linked to tumorigenesis and chemosensitivity in cancers beyond breast cancer. Using paclitaxel-cisplatin-based NAC in a prospective Chinese cohort, expression levels were tested for associations with pathological complete response and multiple survival end points, supported by logistic regression and Kaplan–Meier analyses.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/value-of-cdr1-as-as-a-predictive-and-prognostic-biomarker-for-patients-with-breast-cancer-receiving-neoadjuvant-chemotherapy-research-findings/340038/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/value-of-cdr1-as-as-a-predictive-and-prognostic-biomarker-for-patients-with-breast-cancer-receiving-neoadjuvant-chemotherapy-research-findings/340038.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical problem does the study address?","Question",{"text":112,"@type":113},"The study addresses the lack of effective biomarkers to predict the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was CDR1-AS measured and analyzed?",{"text":117,"@type":113},"CDR1-AS expression was detected using real-time quantitative reverse transcription polymerase chain reaction. Its predictive value for pathological complete response was assessed by logistic regression, while survival relationships were analyzed with Kaplan–Meier, log-rank tests, and Cox proportional hazards models.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main findings regarding CDR1-AS and outcomes?",{"text":121,"@type":113},"Lower CDR1-AS expression was associated with improved pathological complete response and showed better disease-free survival and relapse-free survival. Multivariate analyses indicated CDR1-AS expression as an independent prognostic factor for multiple survival measures.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340038,1791000269,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Yuan et al. European Journal  \nEuropean Journal of Medical Research (2024) 29:454  \n[https://doi.org/10.1186/s40001-024-02015-y](https://doi.org/10.1186/s40001-024-02015-y of Medical Research)[ of Medical Research](https://doi.org/10.1186/s40001-024-02015-y of Medical Research)  \n RESEARCH Open Access  \nValue of CDR1-AS as a predictive and prognostic biomarker for patients  \nwith breast cancer receiving neoadjuvant chemotherapy in a prospective Chinese cohort  \nChenwei Yuan1†, Yaqian Xu2†, Liheng Zhou1*, Jing Peng1, Rui Sha1, Yanping Lin1, Shuguang Xu1, Yumei Ye1, Fan Yang1, Tingting Yan1, Xinrui Dong1, Yaohui Wang1*, Wenjin Yin1 and Jinsong Lu 1*  \nAbstract  \nBackground Neoadjuvant chemotherapy (NAC) is an effective treatment for locally advanced breast cancer (BC) . However, there are no effective biomarkers for evaluating its efficacy. CDR1-AS, well known for its important role in tumorigenesis, is a famous circular RNA involved in the chemosensitivity of cancers other than BC. However, the predictive role of CDR1-AS in the efficacy and prognosis of NAC for BC has not been fully elucidated. We herein aimed to clarify this role.  \nMethods The present study included patients treated with paclitaxel-cisplatin-based NAC. The expression of CDR1-AS was detected by real-time quantitative reverse transcription polymerase chain reaction testing. The predictive value of CDR1-AS expression was examined in pathological complete response (pCR) after NAC using logistic regression analysis. The relationship between CDR1-AS expression and survival was demonstrated using the Kaplan–Meier method, and tested by log-rank test and Cox proportional hazards regression model.  \nResults The present study enrolled 106 patients with BC. Multivariate logistic regression analysis revealed that CDR1-AS expression was an independent predictive factor for pCR (odds ratio [OR] = 0 . 244; 95% confidence interval [CI] 0.081–0. 732; p = 0. 012) . Furthermore, pCR benefits with low CDR1-AS expression were observed across all subgroups. The Kaplan–Meier curves and log-rank test suggested that the CDR1-AS high-expression group showed significantly better disease-free survival (DFS; log-rank p = 0. 022) and relapse-free survival (RFS; log-rank p = 0 . 012) than the CDR1-AS low-expression group. Multivariate analysis revealed that CDR1-AS expression was an independent prognostic factor for DFS (adjusted HR = 0 . 177; 95% CI 0.034–0. 928, p = 0 . 041), RFS (adjusted HR = 0 . 061; 95% CI 0.006–0. 643, p = 0 . 020), and distant disease-free survival (adjusted HR = 0 . 061; 95% CI 0 .006–0. 972, p = 0 . 047) .  \n†Chenwei Yuan andYaqian Xu have contributed equally to this paper.  \n*Correspondence:  \nLiheng Zhou [kaneshiro_lily@hotmail.com](kaneshiro_lily@hotmail.com)[ ](kaneshiro_lily@hotmail.com)Yaohui Wang [wangyaohui@renji.com](wangyaohui@renji.com)[ ](wangyaohui@renji.com)Jinsong Lu[lujingsong@renji.com](lujingsong@renji.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licen","cbCaicKhKXs0NGZx","https://ap.wps.com/l/cbCaicKhKXs0NGZx","pdf",1509202,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Rationale for biomarkers in NAC","[{\"question\":\"What clinical problem does the study address?\",\"answer\":\"The study addresses the lack of effective biomarkers to predict the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer patients.\"},{\"question\":\"How was CDR1-AS measured and analyzed?\",\"answer\":\"CDR1-AS expression was detected using real-time quantitative reverse transcription polymerase chain reaction. Its predictive value for pathological complete response was assessed by logistic regression, while survival relationships were analyzed with Kaplan–Meier, log-rank tests, and Cox proportional hazards models.\"},{\"question\":\"What were the main findings regarding CDR1-AS and outcomes?\",\"answer\":\"Lower CDR1-AS expression was associated with improved pathological complete response and showed better disease-free survival and relapse-free survival. Multivariate analyses indicated CDR1-AS expression as an independent prognostic factor for multiple survival measures.\"}]","Value of CDR1-AS as a predictive and prognostic biomarker for patients with breast cancer receiving neoadjuvant chemotherapy - Research findings | PDF",1790033858,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/107955f328080e008d391c4fa618a437.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/12934d09a32107bd4f7b10274e36908f.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/49c8f418044874a0c9b1ce60ed2d0b34.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/acf71fc8ef05c8b40229f9291891e5c8.webp",980,1301]